# --SuPERIOR Trial--

> **NCT06191250** · PHASE2 · TERMINATED · sponsor: **University Health Network, Toronto** · enrollment: 10 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)
- Clinical Staging T2b-3 N0-1 M0

## Interventions

- **DRUG:** Durvalumab
- **RADIATION:** Non-ablative oligofractionated radiation (NORT)

## Key facts

- **NCT ID:** NCT06191250
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-09-28
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Study Terminated Prior to trial activation, due to changes in SOC of the treatment
- **Last updated:** 2025-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06191250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06191250, "--SuPERIOR Trial--". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06191250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*